Clinical trials recruiting for Moderate to Severe Plaque Psoriasis
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Bimekizumab | 1 |
| Deucravacitinib | 1 |
| Drug group:vunakizumab (IL-17A inhibitor) | 1 |
| Drug:WD-890 | 1 |
| Tyk2 inhibitor | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 1 |
| Florida | 1 |
| Massachusetts | 1 |
| North Carolina | 1 |
| Wisconsin | 1 |
Top cities
Self-screener
Recruiting trials
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
- A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
- Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
- Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Related conditions
Trials recruiting for Moderate to Severe Plaque Psoriasis often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Moderate to Severe Plaque Psoriasis trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.